-- Innovent Biologics (HKG:1801) recorded a 50% year over year growth in total product revenue during the first quarter of 2026, according to a Hong Kong bourse filing Thursday.
The firm generated 3.8 billion yuan in total product revenue during the period on the back of its oncology pipeline and general biomedicine franchise.